TAMPA, FL--(Marketwire - April 02, 2009) - Today, Stem Cell Therapy International Inc.
(OTCBB: SCII) -- soon to be known as AmStem International after a
successful merger with Histostem Ltd, of South Korea ("the Company") -- is
proud to announce its first new product, a cosmetic face cream made with
"This will launch AmStem into the multi billion dollar annual wholesale
cosmetic market," informed David Stark, President of AmStem. "It will also
provide an influx of capital to our new business, to provide a boost for
launching our plans for expansion in other areas."
The stem cell face cream is to be sold wholesale to major cosmetic
distributors worldwide; focusing on the U.S. and European Union. Mr.
Stark's proven experience with regulatory agencies -- he is an accredited
college professor, teaching a course in U.S. regulations -- will provide
the insight and guidance needed to clear the hurdles for bringing this new
product to millions.
"Our new stem cell face cream is an end result of many years in the
laboratory, where our stem cell lines have been developed from our own cord
blood repository," explained Dr. Hoon Han, CEO of Histostem, Ltd. in South
Korea. "Our own studies have shown that this cream is safe and effective
in rejuvenating the skin and providing excellent health for facial
"I'm very excited about being able to hit the ground running with our new
Company," added Mr. Stark. "This will be the first of many innovations
that AmStem will bring to the booming market for stem cells, and with our
power base as the world's largest repository of cord blood, we have the
depth and resources to generate even more products from our GMP-ready
About Stem Cell Therapy International, Inc.
Stem Cell Therapy International, Inc. ('SCII') is in the field of
regenerative medicine. SCII is a company devoted to the treatment of
patients with stem cell transplantation therapy as well as providing the
supplies of biological solutions containing new lines of stem cell
products. Further information about Stem Cell Therapy International, Inc.
can be found at its website www.scticorp.com.
About Histostem Corporation, Ltd:
Histostem, Co., Ltd. started in Seoul, Korea in 2000. To date it has
treated more than 500 patients with stem cells and currently have 56
full-time employees and 28 part-time employees. Histostem's intellectual
property portfolio consists of five patents that have been granted and 6
patents pending. To its knowledge Histostem is one of the very few stem
cell companies in the world currently earning several million dollars in
income from its products and technology. A comprehensive list of
Histostem's achievements can be found at the company's website
http://www.histostem.co.kr (click on English version when entering the
Some of the statements included in this press release, particularly those
anticipating future clinical and business prospects for Stem Cell Therapy
International, Inc. may be forward-looking statements that involve a number
of risks and uncertainties. For those statements, we claim the protection
of the safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Among the factors that could
cause our actual results to differ materially are the following: our
ability to obtain necessary capital, our ability to successfully complete
the merger, successfully complete clinical trials; our ability to meet
anticipated development timelines, our ability to establish global market
for the cord blood cells, clinical trial results, successfully consummate
future acquisitions, manufacturing capabilities or other factors; and other
risk factors identified from time to time in our reports filed with the
Securities and Exchange Commission. Any forward-looking statements set
forth in this press release speak only as of the date of this press
release. We do not intend to update any of these forward-looking statements
to reflect events or circumstances that occur after the date hereof.